Fig. 1
From: Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy
RTKs are prognostic factors for immune “hot” pancreatic cancer. A-B Overall survival analyses of patients with high and low EGFR expression in CD8 + T-cell-enriched pancreatic cancer (A) and CD8 + T-cell-decreased pancreatic cancer (B). C-D Overall survival analyses of patients with high and low MET expression in CD8 + T-cell-enriched pancreatic cancer (C) and CD8 + T-cell-decreased pancreatic cancer (D). E Prognostic landscape of RTKs in pancreatic cancer. All RTKs with a significant prognostic role are shown